National Bank of Canada
CADL icon

National Bank of Canada’s Candel Therapeutics CADL Stock Holding History

National Bank of Canada’s Portfolio CADL Stock Details CADL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3
Closed -$21 – 2963
2024
Q3 		$21 Buy
+3
New +$19 ﹤0.01% 2641

Other funds holding CADL

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PCM
Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return
HFF
Halter Ferguson Financial Carmel, Indiana $456M AUM 49.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

National Bank of Canada's CADL Position: Q4 2024 in Review

National Bank of Canada sold out of Candel Therapeutics (CADL) in Q4 2024, closing a stake of 3 shares — an estimated $21 sold.

National Bank of Canada first reported a position in CADL in Q3 2024 and held it in 1 quarter. The position peaked at $21 in Q3 2024. 71 funds tracked by Wall St. Rank hold CADL as of Q4 2024.

  • National Bank of Canada reported no remaining Candel Therapeutics position as of Q4 2024 after selling out during the quarter.
  • National Bank of Canada sold 3 Candel Therapeutics shares in Q4 2024, an estimated $21.
  • National Bank of Canada first reported a position in Candel Therapeutics in Q3 2024 and held it in 1 quarter.
  • National Bank of Canada's Candel Therapeutics position peaked at $21 in Q3 2024.
  • 71 funds tracked by Wall St. Rank held Candel Therapeutics as of Q4 2024.

Based on National Bank of Canada's 13F filing for Q4 2024, filed 12 Feb 2025.